Close
Blog & Resources Camargo Blog September 14th, 2009

A Treatment IND is NOT the Same as an IND

In this blog I seldom quote or provide hyperlinks to press reports because they too often contain misleading information. Yet, today’s DIA web summary contained an article that I just have to correct. The article was a summary of a report on Medpage’s website. The report’s heading is inadvertently correct: “FDA Finds Oral Insulin Spray Safe for IND Use“; in order to commence an IND, the sponsor must convince the Agency that the proposed product is sufficiently safe for testing in humans. What is incorrect is the statement: For a drug to receive IND approval, it must demonstrate efficacy during clinical trials.” Definitely not true since in Phase 1 you only show safety. Phase 2 is where you begin to show efficacy.

Where the authors got it wrong is that Generex is in Phase III trials, requested and received permission from FDA for a treatment IND. This spelled out correctly in the Generex press release.

The FDA provides treatment INDs as a means to allow early drug access to patients who have an unmet critical need when such patients don’t otherwise qualify for the Phase III trial(s).


Categories: Clinical / Regulatory

Get Our Expertise Working for You

To learn how you can benefit from our regulatory and strategic development expertise, view our solutions or contact us.


Camargo Pharmaceutical Services provides comprehensive drug development solutions, specializing in customized programs including the 505(b)(2) pathway.


Contact
Headquarters
9825 Kenwood Road
Suite 203
Cincinnati OH, 45242
Durham Office
2505 Meridian Parkway
Suite 150
Durham NC, 27713
Phone 513.561.3329
Toll Free 888.451.5708
Subscribe for our Latest Insights